Omega-3 polyunsaturated fatty acid supplementation and non-alcoholic fatty liver disease A meta-analysis of randomized controlled trials

Background: Clinical trials examining the therapeutic benefit of omega-3 polyunsaturated fatty acids (omega-3 PUFAs) on nonalcoholic fatty liver disease (NAFLD) have reported inconsistent results. We performed a meta-analysis of randomized controlled trials (RCTs) examining the effect of omega-3 PUFA supplementation on NAFLD, and provide substantial evidence on whether omega-3 PUFA supplementation has a favorable effect for treating NAFLD. Methods: We searched the PubMed, Cochrane Library, Springer Link, China National Knowledge Infrastructure (CNKI), Wanfang, and Chinese Scientific and Technological Journal (VIP) databases for RCTs on oral omega-3 PUFA supplementation in patients with NAFLD. The data were pooled; meta-analyses were conducted using random-effect or fixed-effect models. Results: Eighteen studies involving 1424 patients were included. We found a significant benefit for omega-3 PUFAs vs control for liver fat, alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transferase, triglycerides, insulin resistance, and glucose. However, there was significant interstudy heterogeneity. Subgroup and regression analyses showed no significantly clear methodologic discrepancy. Publication bias and serious adverse events were not detected. Conclusions: Our meta-analysis suggests that omega-3 PUFA supplementation may decrease liver fat and hepatic enzyme parameters. However, more large-scale, well-designed RCTs are needed to confirm the effect of omega-3 PUFA supplementation on these parameters.